Katerina Kubackova

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management.

Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management.

Journal: Pathology oncology research : POR

Published: January 12, 2017

Clinical and Functional Importance of Selected CASP8 and CASP9 Polymorphisms in Breast Carcinoma

Clinical and Functional Importance of Selected CASP8 and CASP9 Polymorphisms in Breast Carcinoma

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: December 14, 2016

Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.

Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.

Journal: Drugs & aging

Published: August 20, 2016

Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)

Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: August 19, 2016

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.

Journal: The oncologist

Published: April 06, 2016

Role of the Immune System and Possibilities of Immunotherapy in Prostate Cancer

Role of the Immune System and Possibilities of Immunotherapy in Prostate Cancer

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: December 10, 2015

Heterologous expression of human cytochrome P450 2S1 in Escherichia coli and investigation of its role in metabolism of benzo[a]pyrene and ellipticine.

Heterologous expression of human cytochrome P450 2S1 in Escherichia coli and investigation of its role in metabolism of benzo[a]pyrene and ellipticine.

Journal: Monatshefte fur chemie

Published: November 19, 2015

Induced expression of microsomal cytochrome b5 determined at mRNA and protein levels in rats exposed to ellipticine, benzo[a]pyrene, and 1-phenylazo-2-naphthol (Sudan I).

Induced expression of microsomal cytochrome b5 determined at mRNA and protein levels in rats exposed to ellipticine, benzo[a]pyrene, and 1-phenylazo-2-naphthol (Sudan I).

Journal: Monatshefte fur chemie

Published: October 24, 2015

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.

Journal: European urology

Published: July 19, 2015

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.

Journal: Targeted oncology

Published: April 24, 2015

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 11, 2015

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.

Journal: Oncotarget

Published: February 10, 2015

Showing 1-12 of 25

Last Updated: 09/26/2026